Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients
Conditions
Interventions
CJM112
Secukinumab
+1 more
Locations
18
United States
Novartis Investigative Site
Anniston, Alabama, United States
Novartis Investigative Site
Anaheim, California, United States
Novartis Investigative Site
Encino, California, United States
Novartis Investigative Site
North Hollywood, California, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Miami, Florida, United States
Start Date
June 1, 2013
Primary Completion Date
October 1, 2015
Completion Date
October 1, 2015
Last Updated
December 11, 2020
NCT04207801
NCT00941031
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions